📊 ENSCW Key Takeaways
Is Ensysce Biosciences, Inc. (ENSCW) a Good Investment?
Ensysce Biosciences is a severely distressed pharmaceutical company with minimal revenue ($3.2M), massive operating losses (-$7.5M), and a -232.6% net margin indicating the business is burning cash at an unsustainable rate. With negative free cash flow of -$6.4M and only $1.7M in cash reserves against $2.3M in liabilities, the company faces imminent liquidity constraints and potential insolvency without significant capital infusion or operational turnaround.
Ensysce Biosciences shows extremely weak fundamentals, with minimal revenue relative to its cost base, deeply negative operating and net margins, and persistent cash burn that materially exceeds its revenue. While the balance sheet is not debt-heavy, the company's small cash position and low equity base suggest continued dependence on external financing unless operating losses narrow substantially.
Why Buy Ensysce Biosciences, Inc. Stock? ENSCW Key Strengths
- Positive current ratio of 1.27x provides short-term liquidity cushion
- No long-term debt reduces leverage risk and balance sheet complexity
- Cash position of $1.7M provides runway for near-term operations
- Debt-free capital structure reduces balance-sheet leverage risk
- Current and quick ratios above 1.0 indicate near-term obligations are currently covered
- Reported revenue is stable year over year, providing at least some non-zero top-line base
ENSCW Stock Risks: Ensysce Biosciences, Inc. Investment Risks
- Revenue of $3.2M is insufficient to cover operating expenses of $10.7M, indicating fundamental business model failure
- Negative free cash flow of -$6.4M will deplete $1.7M cash reserve in approximately 3 months at current burn rate
- Operating margin of -234.2% and net margin of -232.6% demonstrate the company is not close to profitability
- Zero insider purchases in last 90 days suggests lack of management confidence in the business
- ROE of -615.6% and ROA of -233.0% indicate severe shareholder value destruction
- Operating and net losses are far larger than revenue, indicating an unsustainable business model at current scale
- Negative operating cash flow and free cash flow imply limited cash runway relative to annual burn
- Very low equity base and deeply negative ROE increase dilution and financing risk
Key Metrics to Watch
- Monthly cash burn rate and months of cash runway remaining
- Revenue growth trajectory and path to profitability
- Insider buying activity as indicator of management confidence
- Quarterly operating cash burn relative to cash and equivalents
- Progress in scaling recurring revenue and reducing operating loss
Ensysce Biosciences, Inc. (ENSCW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Ensysce Biosciences, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
ENSCW Profit Margin, ROE & Profitability Analysis
ENSCW vs Healthcare Sector: How Ensysce Biosciences, Inc. Compares
How Ensysce Biosciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Ensysce Biosciences, Inc. Stock Overvalued? ENSCW Valuation Analysis 2026
Based on fundamental analysis, Ensysce Biosciences, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Ensysce Biosciences, Inc. Balance Sheet: ENSCW Debt, Cash & Liquidity
ENSCW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Ensysce Biosciences, Inc.'s revenue has grown significantly by 48% over the 5-year period, indicating strong business expansion. The most recent EPS of $-11.45 indicates the company is currently unprofitable.
ENSCW Revenue Growth, EPS Growth & YoY Performance
ENSCW Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $493.1K | $661.8K | $1.00 |
| Q2 2025 | $181.8K | -$1.7M | $-0.79 |
| Q1 2025 | $305.7K | -$1.9M | $-1.39 |
| Q3 2024 | $435.4K | $661.8K | $0.07 |
| Q2 2024 | $181.8K | -$2.0M | $-0.22 |
| Q1 2024 | $305.7K | -$2.2M | $-0.55 |
| Q3 2023 | $279.4K | -$2.7M | $-0.87 |
| Q2 2023 | $207.5K | -$2.2M | $-0.98 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Ensysce Biosciences, Inc. Dividends, Buybacks & Capital Allocation
ENSCW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Ensysce Biosciences, Inc. (CIK: 0001716947)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ENSCW
What is the AI rating for ENSCW?
Ensysce Biosciences, Inc. (ENSCW) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 94% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ENSCW's key strengths?
Claude: Positive current ratio of 1.27x provides short-term liquidity cushion. No long-term debt reduces leverage risk and balance sheet complexity. ChatGPT: Debt-free capital structure reduces balance-sheet leverage risk. Current and quick ratios above 1.0 indicate near-term obligations are currently covered.
What are the risks of investing in ENSCW?
Claude: Revenue of $3.2M is insufficient to cover operating expenses of $10.7M, indicating fundamental business model failure. Negative free cash flow of -$6.4M will deplete $1.7M cash reserve in approximately 3 months at current burn rate. ChatGPT: Operating and net losses are far larger than revenue, indicating an unsustainable business model at current scale. Negative operating cash flow and free cash flow imply limited cash runway relative to annual burn.
What is ENSCW's revenue and growth?
Ensysce Biosciences, Inc. reported revenue of $3.2M.
Does ENSCW pay dividends?
Ensysce Biosciences, Inc. does not currently pay dividends.
Where can I find ENSCW SEC filings?
Official SEC filings for Ensysce Biosciences, Inc. (CIK: 0001716947) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ENSCW's EPS?
Ensysce Biosciences, Inc. has a diluted EPS of $-3.42.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ENSCW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Ensysce Biosciences, Inc. has a STRONG SELL rating with 94% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ENSCW stock overvalued or undervalued?
Valuation metrics for ENSCW: ROE of -615.6% (sector avg: 15%), net margin of -232.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ENSCW stock in 2026?
Our dual AI analysis gives Ensysce Biosciences, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ENSCW's free cash flow?
Ensysce Biosciences, Inc.'s operating cash flow is $-6.3M, with capital expenditures of $123.6K. FCF margin is -201.1%.
How does ENSCW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -232.6% (avg: 12%), ROE -615.6% (avg: 15%), current ratio 1.27 (avg: 2).